# Capecitabine and Docetaxel in Advanced/Recurrent Cervical Cancer

> **NCT00257348** · PHASE2 · COMPLETED · sponsor: **University of California, Irvine** · enrollment: 5 (actual)

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00257348
- **Lead sponsor:** University of California, Irvine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2007-07
- **Final completion:** 2007-07
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2013-02-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00257348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00257348, "Capecitabine and Docetaxel in Advanced/Recurrent Cervical Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00257348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*